NEW Own INSM? Track every INSM payout — and your other stocks
Track your stocks, dividends, monitor DRIP shares, and project your passive income.
Start Free »

INSM | NASDAQ

$119.75 $0.00 | 0.00%

Next Earnings: Sep 15, 2026

Company Overview:

Market Cap: $0
Trailing PE: 0x
FWD PE: —
Payout Ratio (TTM): —
52-Week Range: $90.39 - $212.75

6.9 Year INSM Performance Metrics:

Total Return (with DRIP): 554% (31.29% CAGR)
Total Return (no DRIP): 554% (31.29% CAGR)
Share Price: 554% (31.29% CAGR)
Yield on Cost (with DRIP): —
Total Invested: $10,000
Total Value (with DRIP): $65,437
Total Return $ (with DRIP): $55,437
INSM Total Return
1Y 2Y 5Y 10Y All
INSM Price Chart
1Y 2Y 5Y 10Y All
DRIPCalc.com
INSM Price

Unlock All Reports & Research Dividend Stocks.

Save 25% with annual plan (3 Months Free)
Pro
$171/yr ($14.25/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Stock Fundamentals
  • DCF valuation modeling
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
Start Free Trial
You save $57/yr (25%)
Most Popular
Premium
$288/yr ($24/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • Stocks Dashboard
Start Free Trial
You save $96/yr (25%)
Ultra
$576/yr ($48/mo)
7-day free trial
  • Everything in Premium
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Start Free Trial
You save $192/yr (25%)

INSM Earnings, Revenue, Cash & Debt, Shares Outstanding:

INSM - Revenue
INSM Revenue CAGR:1Y: 296.11%2Y: 117.02%5Y: 56.47%10Y: 0.00%
INSM - Earnings Per Share (EPS)
INSM EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
INSM - Net Income
🔒 Unlock
INSM Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
INSM - EBITDA
🔒 Unlock
INSM EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
INSM - Free Cash Flow
🔒 Unlock
INSM Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
INSM - Free Cash Flow / Share
🔒 Unlock
INSM Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
INSM - Operating Income
🔒 Unlock
INSM Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
INSM - Gross Profit
🔒 Unlock
INSM Gross Profit CAGR:1Y: 351.57%2Y: 129.35%5Y: 0.00%10Y: 0.00%
INSM - Shares Outstanding
🔒 Unlock
INSM Shares Outstanding CAGR:1Y: 14.82%2Y: 18.53%5Y: 14.68%10Y: 13.39%
INSM - Share Buybacks
🔒 Unlock
INSM Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
INSM - Stock-Based Comp
🔒 Unlock
INSM Stock-Based Comp CAGR:1Y: -4.01%2Y: 33.10%5Y: 28.59%10Y: 24.49%
INSM - Expenses
🔒 Unlock
INSM Expenses CAGR:1Y: 79.65%2Y: -3.94%5Y: 12.42%10Y: 15.05%
INSM - Revenue vs Net Income
🔒 Unlock
INSM - EPS vs FCF / Share
🔒 Unlock
INSM - EPS vs PE Ratio
🔒 Unlock
INSM - FCF vs FCF / Share
🔒 Unlock
INSM - FCF vs Stock Based Comp
🔒 Unlock
INSM - Cash & Debt
🔒 Unlock
INSM - Revenue by Segment
🔒 Unlock
INSM Revenue CAGR:1Y: 296.11%2Y: 117.02%5Y: 56.47%10Y: 0.00%
INSM - Revenue by Region
🔒 Unlock
INSM Revenue CAGR:1Y: 296.11%2Y: 117.02%5Y: 56.47%10Y: 0.00%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

INSM - REVENUE: Actual + Estimates
🔒 Unlock
INSM Actual Revenue CAGR:1Y: 296.11%2Y: 117.02%5Y: 56.47%10Y: 0.00%
INSM - EPS: Actual + Estimates
🔒 Unlock
INSM Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
INSM - NET INCOME: Actual + Estimates
🔒 Unlock
INSM Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
INSM - EBITDA: Actual + Estimates
🔒 Unlock
INSM Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

INSM - Net Profit Margin
🔒 Unlock
INSM Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
INSM - Gross Profit Margin
🔒 Unlock
INSM Gross Profit Margin CAGR:1Y: 14.00%2Y: 5.67%5Y: 2.04%10Y: 0.00%
INSM - Price to Earnings
🔒 Unlock
INSM - Price To Sales Ratio
🔒 Unlock
INSM - Return on Capital Employed
🔒 Unlock
INSM - Return on Invested Capital
🔒 Unlock
Compare stocks side-by-side
 

Projected Future Returns & Dividends for INSM

Based on past 6.9-year performance, here are INSM growth metrics:

Share price CAGR of +31.29%
Dividend CAGR of +0%

Using INSM CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, is modelled to grow as follows:

INSM (DRIP)INSM - No DRIP
Current Price$119.75$119.75
Start Shares83.5183.51
Start Value$10,000$10,000
  
After 10 years:
Final Share Count83.5183.51
Dividends Payment$0.00$0.00
Annual Dividends$0$0
Yield on cost0.00%0.00%
Share Price$119.75$119.75
Total Dividends$0$0
Final Value$10,000$10,000

Estimated Future Value + Dividends - INSM

NOTE: Above numbers are our estimate based on INSM's Dividend and Price CAGR over past 6.9 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)
Pro
$171/yr ($14.25/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Stock Fundamentals
  • DCF valuation modeling
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
Start Free Trial
You save $57/yr (25%)
Most Popular
Premium
$288/yr ($24/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • Stocks Dashboard
Start Free Trial
You save $96/yr (25%)
Ultra
$576/yr ($48/mo)
7-day free trial
  • Everything in Premium
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Start Free Trial
You save $192/yr (25%)

Company Info

Insmed Incorporated (INSM) had its IPO on 2000-06-01, and is trader on NASDAQ stock exchange.

Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.

INSM website: https://www.insmed.com

Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)
Pro
$171/yr ($14.25/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Stock Fundamentals
  • DCF valuation modeling
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
Start Free Trial
You save $57/yr (25%)
Most Popular
Premium
$288/yr ($24/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • Stocks Dashboard
Start Free Trial
You save $96/yr (25%)
Ultra
$576/yr ($48/mo)
7-day free trial
  • Everything in Premium
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Start Free Trial
You save $192/yr (25%)